我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Les Laboratoires Servier SAS
相关临床试验
33
17 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2000
进行中（未招募）
17
51.5%
已完成
10
30.3%
终止
3
9.1%
撤回
暂无批准数据
• The LAG-3 inhibitors market is poised for substantial growth, projected to exceed USD 3 billion by 2029, driven by increasing adoption in cancer therapy. • Opdualag, the first approved LAG-3 therapy, has demonstrated significant commercial success, generating substantial revenue and paving the way for further drug development. • Clinical trials are actively evaluating LAG-3 inhibitors in combination with other therapies, showing potential across various cancers, autoimmune disorders, and inflammatory diseases. • Several LAG-3 inhibitor candidates are in late-stage clinical trials, indicating a robust pipeline and growing interest from major pharmaceutical companies.
